LATS1 suppresses proliferation and invasion of cervical cancer

Introduction

Cervical cancer is the third most common malignancy in women worldwide, with a global incidence of 500,000 and a mortality of 250,000 in 2014 (1). For the earliest stage of cervical cancer, >90% of women survive at least 5 years after diagnosis. However, advanced cervical cancer with invasion or metastasis is associated with a poor prognosis, <20% of stage IV patients survive for ≥5 years (2). Furthermore, despite advances of conventional therapies such as surgical treatment, radiotherapy and chemotherapy, malignant cervical cancers still have high mortality rate, and the mechanism underlying its aggressiveness remains poorly understood. Thus, the identification of novel molecular markers, which is helpful for the development of novel diagnostic and therapeutic strategies, remains an important focus in the current management of this malignancy.

Mammalian Large tumor suppressor kinase 1 (LATS1) and LATS2, the major kinase components of the Hippo pathway, are important in the control of tumor development (3,4) and the cell cycle, via various mechanisms and signaling pathways (5,6). It was previously reported that LATS1 protein was downregulated in various types of cancer, including breast carcinoma (7), colorectal carcinoma (8), gastric cancer (9), non-small cell lung cancer (10) and ovarian serous carcinoma and clear cell carcinoma (11). These results indicated that LATS1 may be an important tumor suppressor in types of human cancer. However, whether LATS1 is a tumor suppressor in cervical cancer remains controversial.

The present study examined LATS1 protein expression in 80 cases of cervical carcinoma and analyzed the association between LATS1 expression and clinicopathological factors. Additionally, gain of function and loss of function experiments were performed to investigate the biological roles of LATS1 in cervical cancer. LATS1 expression was upregulated in SiHa cells and depleted in Caski cells, and the effects on cell proliferation and invasion were then examined. In addition, the molecular signaling pathways underlying these biological effects of LATS1 were investigated.

Materials and methods

Patients and specimens

The protocol of the current study was approved by the Institutional Review Board of Kunming Maternity and Child Care Hospital (Kunming, China). Primary tumor specimens were obtained from 80 patients (mean age, 45.5; range, 28–72) diagnosed with cervical carcinoma who underwent resection in Kunming Maternity and Child Care Hospital between January 2012 and November 2014. Informed consent was obtained. Histological diagnosis was performed on sections stained with hematoxylin and eosin, according to the World Health Organization classification guidelines (12). Clinical and histopathological data were obtained from medical records.

Immunohistochemistry

Cervical cancer tissue specimens were fixed in 10% formalin at room temperature for 24 h and embedded in paraffin. Immunohistochemistry was carried out using Elivision™ plus Polyer HRP IHC kit (Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China) according to the manufacturer-s protocol. Briefly, 4 µm thick tissue sections were deparaffinized and rehydrated using ethanol. Subsequently, antigen retrieval was performed using 0.01 M citrate buffer (pH 6.0) for 2 min. H2O2 was employed to inhibit endogenous peroxide and non-immune goat serum (Fuzhou Maixin Biotech Co., Ltd.) was used to reduce non-specific antibody binding at room temperature for 15 min. Sections were then incubated with LATS1 antibody (1:200; cat. no. 9153; Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C overnight. Biotinylated anti-rabbit horseradish peroxidase polymer (ready to use; cat. no. 9922; Fuzhou Maixin Biotech Co., Ltd.) was used as a secondary antibody at 37°C for 2 h. Following washing, the peroxidase reaction was developed with 3, 3-diaminobenzidine. Counterstaining with hematoxylin was performed and the sections were dehydrated in ethanol prior to mounting.

Two independent blinded investigators examined all tumor slides randomly. As in previous studies (13,14), immunostaining of LATS1 was scored on a semi-quantitative scale by evaluating the intensity and percentage of tumor cells stained. Cytoplasmic immunostaining was regarded as positive. The intensity of LATS1 staining was scored as follows: 0, weak/negative; 1, moderate; or 2 (strong). Staining percentage, the percentage of tumor cells stained, was scored as follows: 1, 1–25%; 2, 26–50%; 3, 51–75%; or 4, 76–100%. Total score was obtained by multiplying the staining and percentage scores. Specimens with a total score of 5–8 were considered to be positive for LATS1 expression. Specimens with a total score of 0–4 were considered to have low LATS1 expression.

Cell culture and transfection

Caski, HeLa and SiHa cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). SiHa and HeLa cells were cultured in minimum essential medium (MEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and Caski cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37°C for 2 days. Cells were cultured on sterilized culture plates and were passaged every two days with trypsin.

The plasmid of pCMV6-LATS1 was purchased from (OriGene Technologies, Inc. (Rockville, MD, USA) Plasmid was transfected into cells using Lipofectamine® 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 48 h. pCMV6 empty vector was used as a negative control. For transient knockdown experiments, oligonucleotide pools of small interfering RNA (siRNA) targeting LATS1 and non-targeting siRNA (cat. no. M-004632-00-0005) were purchased from Dharmacon (Lafayette, CO, USA) and transfected using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 48 h, according to the manufacturers- protocols.

Western blot analysis

Proteins were extracted and quantified using the Bradford method, and 20 µg protein was separated by SDS-PAGE (5% stacking gel and 10% separating gel). Proteins were transferred to polyvinylidene fluoride membranes and 5% BSA solution (w/v) was used to reduce non-specific antibody binding at room temperature for 1 h. Proteins were incubated overnight at 4°C with antibodies against LATS1 (1:1,000; cat. no. 9153; Cell Signaling Technology, Inc.), phosphorylated-yes associated protein 1 (p-YAP; 1:1,000; cat. no. 4911; Cell Signaling Technology, Inc.), YAP (1:1,000; cat. no. 4912; Cell Signaling Technology, Inc.), p27 (1:1,000; cat. no. 2552; Cell Signaling Technology, Inc.), cyclin E (1:1,000; cat. no. 20808; Cell Signaling Technology, Inc.), connective tissue growth factor (CTGF; 1:1,000; 23936-1-AP; Proteintech, Chicago, Illinois, USA) and matrix metalloproteinase 9 (MMP9; 1:1,000; cat. no. 3852; Cell Signaling Technology, Danvers, MA, USA) and GAPDH (1:1,000; cat. no. sc-25778; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). PVDF membranes were washed using TBST solution (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) three times for 5 min each. Following incubation with peroxidase-coupled anti-mouse/rabbit IgG (1:2,000; cat. no. 5127/58802; Cell Signaling Technology, Inc., Danvers, MA, USA) at 37°C for 2 h, proteins were visualized using SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific, Inc.) and detected using a DNR Bio-Imaging System (DNR Bio-Imaging Systems, Ltd., Jerusalem, Israel).

MTT assay

Cells were plated in 96-well plates in MEM containing 10% fetal bovine serum at approximately 1,000–1500 cells per well. For the measurement of cell viability, 20 µl MTT solution was added to each well and incubated at 37°C for 4 h. Subsequently, the remaining MTT formazan was dissolved in 150 µl dimethyl sulfoxide. The plate was measured at a wavelength of 490 nm using a plate reader.

Cell invasion analysis

Cell invasion was examined using Transwell assay with 24-well Transwell chambers. Briefly, Transwell chamber inserts were coated using 20–25 µl Matrigel from BD Biosciences (Franklin Lakes, NJ, USA) with a dilution of 1:5. ~48 h after cell transfection, ~1×105 cells were re-suspended in 100 µl of serum-free MEM and were added to the upper chamber. MEM with 10–15% fetal bovine serum was added to the lower chamber. After incubation at 37°C for 16–20 h, cells on the upper side of membranes were removed using a cotton swab and the cells that had invaded through the filter were washed with phosphate-buffered saline and visualized with hematoxylin at room temperature for 5 min. The number of invaded cells was counted in 5 randomly selected high power fields using a light microscope. This experiment was performed in triplicate.

Statistical analysis

SPSS version 11.5 for Windows (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses. Data was presented as mean ± standard deviation. χ2 test was used to examine potential associations between LATS1 expression and clinicopathological factors and a paired Student-s t-test was used to compare other data generated from LATS1-transfected or knockdown cells. P<0.05 was considered to indicate a statistically significant difference.

Results

Clinical significance of LATS1 in human cervical cancer

LATS1 expression was located in the cytoplasm in normal cervical tissues (Fig. 1A). Of the 80 cervical cancer tissues, 46 of them (45%) exhibited decreased LATS1 staining, although others were positive for LATS1 expression (Fig. 1B-D). The potential association of low LATS1 expression with clinicopathological characteristics was analyzed. The results demonstrated that low LATS1 immunostaining in cervical cancer was significantly associated with primary tumor, node, metastasis (TNM) stage (stages II+III vs. stage I, P=0.0102) and primary tumor (T) stage (TII+III vs. TI, P=0.0217). No significant association was identified between low LATS1 expression and other parameters, including age, histological type and differentiation (Table I).

Figure 1. Expression of LATS1 protein in cervical cancer tissues. (A) Strong LATS1 expression in normal cervical tissue. (B) Positive LATS1 expression in a case of stage II cervical cancer. (C) Negative staining of LATS1 in a case of stage III cervical cancer. (D) Weak LATS1 expression in a case of stage I adenocarcinoma. Magnification, ×400. LATS1, large tumor suppressor kinase 1.

Table I. Distribution of LATS1 status in cervical carcinoma according to clinicopathological characteristics.

Table I.

Distribution of LATS1 status in cervical carcinoma according to clinicopathological characteristics.

Characteristic	Total number of patients	Number of patients with low LATS1 expression	Number of patients with positive LATS1 expression	P-value
Age				0.5445
<50	55	29	26
≥50	25	15	10
Histological type				0.4552
Squamous cell carcinoma	71	38	33
Adenocarcinoma	9	6	3
Differentiation				0.2905
Well/moderate	58	34	24
Poor	22	10	12
TNM stage				0.0102
I	32	12	20
II+III	48	32	16
T stage				0.0217
T1	42	18	24
T2+3	38	26	12
Lymph node metastasis				0.2458
Negative	50	25	25
Positive	30	19	11

[i] The P-value compares the patients with high expression of LATS1 in different groups. LATS1, large tumor suppressor kinase 1; TNM, primary tumor, node, metastasis; T stage, primary tumor stage.

LATS1 suppresses proliferation and invasion of cervical cancer cells

LATS1 was examined by western blot analysis in cervical cancer cell lines (Fig. 2A). The present study demonstrated that SiHa cells had low LATS1 protein expression and Caski cells had relatively high LATS1 protein expression. To determine its biological roles in cervical cancer cell lines, plasmid transfection was performed in SiHa cells and siRNA knockdown was performed in Caski cells. As presented in Fig. 2B, LATS1 transfection increased protein levels of LATS1 in SiHa cells and siRNA reduced LATS1 protein levels in Caski cells. The MTT assay demonstrated that LATS1 upregulation significantly decreased cell growth rate compared with cells treated with empty plasmid. (SiHa:P=0.019; Caski:P=0.006, Fig. 3A). A Matrigel invasion assay was also performed to assess the effect of LATS1 on cell invasion. As presented in Fig. 3B, LATS1 transfection significantly decreased the invasiveness of SiHa cells compared with cells transfected with empty plasmid (P=0.007), while LATS1 knockdown significantly increased the invasiveness of Caski cells compared with cells treated with negative siRNA (P=0.005).

Figure 2. LATS1 transfection efficiency in cervical cancer cell lines. (A) Western blot analysis demonstrated strong LATS1 expression in the Caski cell line and weak LATS1 expression in the SiHa cell line. (B) Western blot analysis demonstrated that LATS1 transfection in SiHa cells upregulated LATS1 protein expression, and siRNA knockdown in Caski cells downregulated LATS1 protein expression, compared with controls. LATS1, large tumor suppressor kinase 1; siRNA, small interfering RNA.

Figure 3. LATS1 inhibits proliferation and invasion of cervical cancer cells. (A) MTT assay demonstrated that LATS1 transfection significantly reduced cell proliferation in the SiHa cell line (*P<0.05 vs. empty plasmid control), while LATS1 knockdown significantly increased cell proliferation in the Caski cell line (*P<0.05 vs. negative siRNA control). (B) Matrigel invasion assay demonstrated that LATS1 transfection in SiHa cells significantly decreased the number of invading cells (*P<0.05 vs. empty plasmid control), while LATS1 knockdown in Caski cells significantly increased the invasiveness of Caski cells (*P<0.05 vs. negative siRNA control). LATS1, large tumor suppressor kinase 1; siRNA, small interfering RNA.

LATS1 regulates the expression of cyclin E, p27, MMP9 and YAP in cervical cancer cells

In order to investigate the molecular mechanism underlying LATS1-induced cell growth and invasion, the present study examined the expression of growth and invasion-associated proteins. The results demonstrated that the cyclin E expression was notably decreased following LATS1 overexpression in SiHa cells, compared with cells treated with empty plasmid, and increased following LATS1 knockdown in Caski cells, compared with cells treated with negative siRNA. Protein expression of cell cycle inhibitor p27 was increased compared to control following LATS1 transfection in SiHa cells and decreased compared to the control following LATS1 knockdown in Caski cells. (Fig. 4A). The present study also examined invasion-associated protein MMP9, and demonstrated that MMP9 was downregulated in LATS1-transfected SiHa cells and upregulated in LATS1-knockdown Caski cells, compared to respective controls (Fig. 4A). LATS1 is the upstream inhibitor of Hippo signaling. Activation of the Hippo signaling pathway inhibits the expression and function of YAP oncoprotein and suppresses cancer growth and invasion. The current study examined YAP expression, and its downstream factor CTGF, in LATS1 overexpressing and knockdown cervical cancer cells. As presented in Fig. 4B, in LATS1-transfected SiHa cells, CTGF and YAP levels were decreased, compared to the control SiHa cells. In LATS1 knockdown Caski cells, their expression (YAP and CTGF) was upregulated compared with control Caski cells. Changes in the levels of YAP phosphorylation were also examined. Western blot analysis demonstrated that LATS1 increased the phosphorylation of YAP.

Figure 4. LATS1 inhibits cervical cancer cell proliferation and invasion via regulation of cyclin E, p27, MMP9, YAP and CTGF. (A) Western blot analysis demonstrated that LATS1 transfection downregulated the levels of cyclin E and MMP9, and upregulated p27 expression in SiHa cells compared with the control. LATS1 knockdown in Caski cells upregulated cyclin E and MMP9, and downregulated p27 expression. (B) LATS1 overexpression in SiHa cells decreased YAP and CTGF protein levels, and increased YAP phosphorylation compared with the control. LATS1 knockdown in Caski cells resulted in the opposite effects, which upregulated YAP and downregulated p-YAP. LATS1, large tumor suppressor kinase 1; MMP9, matrix metalloproteinase 9; YAP, yes associated protein 1; p-YAP, phosphorylated YAP; CTGF, connective tissue growth factor; siRNA, small interfering RNA.

Discussion

LATS1 is the mammalian homolog of Drosophila LATS, originally identified as a cell proliferation inhibitor (15). It is a serine/threonine kinase that localizes to the mitotic apparatus. LATS1 may form a complex with cyclin-dependent kinase 1 in early mitosis, decreasing H1 histone kinase activity, which indicates its role as a cell cycle inhibitor (16). LATS1-knockout mice developed sarcomas and ovarian tumors, indicating that it may also function as a tumor suppressor (3). The expression and biological roles of LATS1 have been implicated in a number of human malignancies, including gastric cancer, breast cancer, glioma, renal cell carcinoma and ovarian cancer (9,11,17–19). However, to the best of our knowledge, the involvement of LATS1 in human cervical carcinoma has not been reported. The present study examined LATS1 protein expression in 80 cases of cervical cancer and demonstrated that LATS1 was downregulated in 45% of tissue specimens. Statistical analysis demonstrated that LATS1 downregulation was positively associated with advanced TNM stage and tumor status, indicating that loss of LATS1 is associated with cervical cancer progression. The results of the current study are consistent with previous studies (20–22), indicating that LATS1 may be a potential tumor suppressor in human cervical cancer.

To identify its biological roles in cervical cancer cells, the present study transfected SiHa cells with a LATS1 plasmid and Caski cells were transfected with LATS1 siRNA. Subsequently, the effects on cell proliferation and invasion were examined. Consistent with the immunohistochemical results of the present study, LATS1 transfection significantly inhibited cell growth and invasiveness of SiHa cells, while LATS1 siRNA had the opposite effect in Caski cells. The current study further investigated the potential underlying mechanisms by which LATS1 inhibited cell proliferation and invasion in cervical cancer. Previous studies demonstrated that LATS1 functions as a cell cycle regulator (20,21). Thus, the protein levels of cyclin E and p27 in LATS1-overexpressing SiHa cells and LATS1-knockdown Caski cells were investigated in the present study. The results demonstrated that LATS1 downregulated cyclin E and upregulated p27. Cyclin E facilitates and p27 inhibits cell cycle progression (23,24). Cycle E overexpression is important during cervical cancer proliferation (25), and p27 downregulation has been previously identified in cervical cancer tissues where it may cause cell cycle arrest in cervical cancer cells (26,27). In addition, the present study demonstrated that invasion-associated protein MMP9 was negatively regulated by LATS1 expression. MMP9 is considered to be associated with cervical cancer invasion (28–30). Thus LATS1 may regulate cervical cancer growth and invasion through modulation of cell cycle proteins and MMP9. As LATS1 is the upstream positive regulator of Hippo pathway, the current study investigated changes in the expression levels of downstream proteins, including YAP and CTGF. The results demonstrated that LATS1 overexpression inhibited CTGF and YAP expression, and increased YAP phosphorylation in SiHa cells compared with control SiHa cells. YAP is a positive regulator of growth and invasion in various types of human cancers, including cervical cancer (31). CTGF is the target of YAP and functions as a growth promoter. CTGF has been reported to positively regulate the cell cycle and MMP proteins (32,33). Thus, the role of LATS1 in cervical cancer invasion and proliferation may depend on its regulation on YAP, and its downstream target CTGF.

In conclusion, LATS1 is downregulated in human cervical cancers and LATS1 expression is associated with TNM stage. LATS1 inhibited cervical cancer cell proliferation and invasion, potentially through regulation of p27 and MMP9. LATS1 may activate the Hippo pathway through downregulation of YAP and CTGF. Loss of LATS1 may serve as an indicator of malignant phenotype in human cervical cancer.

Acknowledgements

The present study was supported by the Yunnan Provincial Science and Technology Project Fund (grant no. 2014FB200).

References